Table 2.
Three-way interaction effect of APOE ɛ4, sex and cardiovascular risk on tau deposition
| Predictor variables | EC tau-PET SUVR | ITC tau-PET SUVR | Meta-ROI tau-PET SUVR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Estimate | CI | P-value | Estimate | CI | P-value | Estimate | CI | P-value | |
| FHS-CVD risk | 0.01 | −0.0 to 0.02 | 0.126 | 0.0 | −0.01 to 0.01 | 0.939 | 0.0 | −0.01 to 0.01 | 0.927 |
| APOE (ɛ4+) | 0.28 | −0.14 to 0.70 | 0.187 | 0.15 | −0.15 to 0.45 | 0.317 | 0.10 | −0.15 to 0.34 | 0.425 |
| Sex (female) | 0.23 | −0.12 to 0.58 | 0.195 | 0.12 | −0.13 to 0.37 | 0.358 | 0.07 | −0.14 to 0.27 | 0.525 |
| Time lag | 0.03 | −0.0 to 0.07 | 0.059 | −0.0 | −0.03 to 0.02 | 0.913 | −0.00 | −0.02 to 0.02 | 0.920 |
| APOE (ɛ4+) × FHS-CVD risk | −0.00 | −0.02 to 0.01 | 0.563 | −0.0 | −0.01 to 0.01 | 0.781 | −0.00 | −0.01 to 0.01 | 0.927 |
| Sex (female) × FHS-CVD risk | 0.01 | −0.01 to 0.02 | 0.539 | 0.00 | −0.01 to 0.02 | 0.783 | 0.00 | −0.01 to 0.02 | 0.477 |
| APOE (ɛ4+) × sex (female) | −0.57 | −1.12to−0.01 | 0.048* | −0.33 | −0.73 to 0.06 | 0.099 | −0.23 | −0.55 to 0.10 | 0.175 |
| APOE (ɛ4+) × sex (female) × FHS-CVD risk | 0.04 | 0.01–0.07 | 0.008** | 0.02 | 0.00–0.05 | 0.029* | 0.02 | 0.00–0.04 | 0.042* |
Results from linear regression analysis revealed a significant three-way interaction effect of APOE ɛ4, sex and FHS-CVD risk on tau deposition in the EC, ITC and meta-ROI after adjusting for the time between FHS-CVD risk assessment and tau-PET scan. Significant P-values are presented in bold, where *P <0.05, **P < 0.01, ***P < 0.005. CI = confidence interval; EC = entorhinal cortex; FHS-CVD risk = Framingham Heart Study cardiovascular disease risk; ITC = inferior temporal cortex; SUVR = standardized uptake value ratio.